Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription 02.09.2024 1 Ann Surg Oncol 3 Anticancer Res 1 Br J Dermatol 1 Eur J Dermatol 2 J Am Acad Dermatol 1 J Immunother 2 J Invest Dermatol 4 Melanoma Res 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. GHALI H, Dugan MM, Zager JS
   ASO Author Reflections: Optimizing Line of Therapy with the Melphalan/Hepatic Delivery System for Metastatic Uveal Melanoma.
   Ann Surg Oncol. 2024 Aug 28. doi: 10.1245/s10434-024-16112.
   PubMed        
   
   

   
   Anticancer Res

2. FRACCAROLI A, Barnikel M, Scheubeck G, Buchstab O, et al
   Stealthy Invader: Clinically Inapparent But Rapidly Progressive Multifocal Metastatic Melanoma Unveiled as Root Cause of Liver Failure.
   Anticancer Res. 2024;44:4127-4132.
   PubMed         Abstract available
   
   
3. GAO YU, Wendt S, Krohn S, Alammar M, et al
   Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1.
   Anticancer Res. 2024;44:3843-3848.
   PubMed         Abstract available
   
   
4. MA W, Li Z, Wen J, Yan S, et al
   The Expression and Prognostic Value of Multiple Glucose Transporters in Cutaneous Melanoma.
   Anticancer Res. 2024;44:3747-3756.
   PubMed         Abstract available
   
   

   
   Br J Dermatol

5. YAMAZAKI E, Fujimura T, Takahashi-Watanabe M, Tada S, et al
   Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial.
   Br J Dermatol. 2024 Aug 31:ljae343. doi: 10.1093.
   PubMed        
   
   

   
   Eur J Dermatol

6. CAYUELA L, Pereyra-Rodriguez JJ, Hernandez-Rodriguez JC, Sendin-Martin M, et al
   Non-melanoma skin cancer burden in Spain: a nationwide analysis of incidence trends (1990-2019).
   Eur J Dermatol. 2024;34:392-397.
   PubMed         Abstract available
   
   

   
   J Am Acad Dermatol

7. EVERDELL E, Borok J, Deutsch A, Ren Z, et al
   ATLAS: A positive, high-yield review of patient symptoms most significantly associated with melanoma recurrence.
   J Am Acad Dermatol. 2024 Aug 26:S0190-9622(24)02732.
   PubMed         Abstract available
   
   
8. HOANG M, Mirza FN, Weinstock MA, Qureshi AA, et al
   Incidence of melanoma and its subtypes by census tract-level socioeconomic status: a United States population-based cohort analysis.
   J Am Acad Dermatol. 2024 Aug 23:S0190-9622(24)02729.
   PubMed        
   
   

   
   J Immunother

9. PERSA OD, Hassel JC, Steeb T, Erdmann M, et al
   Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary.
   J Immunother. 2024 Aug 29. doi: 10.1097/CJI.0000000000000537.
   PubMed         Abstract available
   
   

   
   J Invest Dermatol

10. RUTJES C, Mothershaw A, D'Alessandro BM, Primiero CA, et al
    Combining Automated Lesion Risk And Change Assessment Improves Melanoma Detection: A Retrospective Accuracy Study.
    J Invest Dermatol. 2024 Aug 23:S0022-202X(24)02060.
    PubMed        
    
    
11. DEACON DC, Stubben C, Marcacci E, Stone CJ, et al
    Classification of Cutaneous Melanoma and Melanocytic Nevi with microRNA Ratios is Preserved in the Acral Melanoma Subtype.
    J Invest Dermatol. 2024 Aug 23:S0022-202X(24)02063.
    PubMed        
    
    

    
    Melanoma Res

12. STOFF R, Markovic SN, McWilliams RR, Kottschade LA, et al
    Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000000997.
    PubMed         Abstract available
    
    
13. 
    Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum.
    Melanoma Res. 2024;34:473.
    PubMed        
    
    
14. MATTIUZZI C, Lippi G
    The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic.
    Melanoma Res. 2024;34:472.
    PubMed        
    
    
15. KIM I, Oh J, Yoon S, Han MY, et al
    Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea (2004-2019).
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000001000.
    PubMed         Abstract available
    
    

    
    PLoS One

16. WU X, Marmarelis ME, Stephen Hodi F
    Correction: Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma.
    PLoS One. 2024;19:e0309769.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.